African Health Sciences
Makerere University Medical School
Vol. 20, No. 4, 2020, pp. 1849-1856
Bioline Code: hs20146
Full paper language: English
Document type: Research Article
Document available free of charge
African Health Sciences, Vol. 20, No. 4, 2020, pp. 1849-1856
© Copyright 2020 - Kaabouch M et al.
BRAFV600E hot spot mutation in thyroid carcinomas: first Moroccan experience from a single-institution retrospective study|
Kaabouch, Meryem; Chahdi, Hafsa; Azouzi, Naima; Oukabli, Mohammed; Rharrassi, Issam; Boudhas, Adil; Jaddi, Hassan; Ababou, Mouna; Dakka, Nadia; Boichard, Amélie; Bakri, Youssef; Dupuy, Corinne; Bouzidi, Abderrahmane Al & Hassani, Rabii Ameziane El
Background: The incidence of thyroid cancer is increasing worldwide at an alarming rate. BRAFV600E mutation is described
to be associated with a worse prognostic of thyroid carcinomas, as well as extrathyroidal invasion and increased mortality.
Objective: To our knowledge, there are no reported studies neither from Morocco nor from other Maghreb countries regarding
the prevalence of BRAFV600E mutation in thyroid carcinomas. Here we aim to evaluate the frequency of BRAFV600E
oncogene in Moroccan thyroid carcinomas.
Methods: In this Single-Institution retrospective study realized in the Anatomic Pathology and Histology Service in the Military
Hospital of Instruction Mohammed V ‘HMIMV’ in Rabat, we report, using direct genomic sequencing, the assessment
of BRAFV600E in 37 thyroid tumors.
Results: We detected BRAFV600E mutation exclusively in Papillary Thyroid Carcinomas ‘PTC’ with a prevalence of 28% (8
PTC out 29 PTC). Like international trends, Papillary Thyroid Carcinomas ’PTC’ is more frequent than Follicular Thyroid
Carcinomas ‘FTC’ and Anaplastic Thyroid Carcinomas ‘ATC’ (29 PTC, 7 FTC and 1 ATC).
Conclusion: Our finding gives to the international community the first estimated incidence of this oncogene in Morocco
showing that this prevalence falls within the range of international trends (30% to 90%) reported in distinct worldwide geographic
Biomarker; BRAFV600E; Thyroid cancer; Morocco.